StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
BLC-R.BK$4.00-0.50%
Fair $4.00+0.0%

BLC-R.BK

Bangkok Lab And Cosmetic Public Company Limited

Consumer Defensive / Household & Personal ProductsThailand

$4.00

-0.02 (-0.50%)

Fairly Valued+0.0%Fair Value $4.00Fund rank 27/100 · Data gapFallback financials|
SA 52/C
F-Score: 5/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 19%

FCF escenarios

weak_data · normalized FCF $27.4M · quality 47.7/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 18/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

52/100

C

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · BLC-R.BKLocal privado en este navegador · Bangkok Lab And Cosmetic Public Company Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$2.4B

P/E

13.8x

↓

EV/EBITDA

8.6x

↓

ROE

10.4%

↑

Gross Margin

58.6%

↑

Debt/Equity

0.13

↓
52-Week Range$4
$4$5

TradingView lightweight chart

BLC-R.BK price, volumen y niveles de valoración

Último $4.000Periodo -44.4%
Fair value: $4.000

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+10.4%

FCF CAGR

—

FCF margin

-32.7%

FCF / Net income

-3.16x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.67B · net income $173.0M · FCF $-546.0M

2022-FY → 2025-FY

Gross margin

58.6%+2.0% pts

Operating margin

13.7%-0.2% pts

Net margin

10.4%+0.2% pts

FCF margin

-32.7%-42.5% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.67B$1.67B$1.56B$1.41B$1.24B
Net Income$173.0M$173.0M$171.4M$145.4M$125.7M
EBITDA$289.5M$289.5M$287.7M$253.1M$224.1M
EPS0.290.290.290.270.21
Gross Margin58.6%58.6%56.0%56.3%56.6%
Operating Margin13.7%13.7%14.8%14.2%14.0%
Net Margin10.4%10.4%11.0%10.3%10.2%
Balance Sheet
Debt/Equity0.130.130.100.212.03
Current Ratio1.821.82———
Cash Flow
Free Cash Flow$-546.0M$-546.0M$27.4M$65.7M$120.4M
Returns
ROE10.4%10.4%10.3%9.2%46.9%
Valuation
P/E13.7913.7915.4519.07—
EV/EBITDA8.598.599.1412.04—
P/B1.441.441.591.78—
Growth & Yield
Revenue Growth7.1%7.1%10.7%13.5%—
EPS Growth0.0%0.0%7.4%28.9%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

7.0%

razonable

EPS terminal req.

$0.35

Spread vs growth

-7.0%

5Y implied EPS CAGR

8.2%

razonable

EPS terminal req.

$0.43

Spread vs growth

-8.2%

10Y implied EPS CAGR

9.1%

razonable

EPS terminal req.

$0.69

Spread vs growth

-9.1%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +7.0%

Total return

+7.0%

Start / end P/E

12.9x → 13.8x

EPS bridge

0.29 → 0.29

Residual

+0.0%

EPS growth+0.0%
Multiple rerating+7.0%
Dividend+0.0%
Residual / FX / buybacks / cross-term+0.0%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.